Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O95602
UPID:
RPA1_HUMAN
Alternative names:
A190; DNA-directed RNA polymerase I largest subunit; DNA-directed RNA polymerase I subunit A; RNA polymerase I 194 kDa subunit
Alternative UPACC:
O95602; B7Z7T0; D6W5M0; Q0VG05; Q9UEH0; Q9UFT9
Background:
DNA-directed RNA polymerase I subunit RPA1, also known as A190, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is the largest and catalytic core component of RNA polymerase I, primarily responsible for synthesizing ribosomal RNA precursors. This protein, together with the second largest subunit, forms the polymerase active center, crucial for the transcription process.
Therapeutic significance:
RPA1's involvement in Acrofacial dysostosis, Cincinnati type, a disorder affecting craniofacial and limb development, underscores its potential as a therapeutic target. Understanding the role of DNA-directed RNA polymerase I subunit RPA1 could open doors to potential therapeutic strategies.